ľֱ

OB/Gyn

Ovarian Cancer

More in Ovarian Cancer

ASCO's Quality Care Symposium: Chemotherapy Shortage Resulted in Higher Costs

Other studies look at financial toxicity for teen/young adult cancer patients, nausea after chemo

Sep 24, 2024
 A photo of a female hospital pharmacist preparing chemotherapy drugs
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer

Poorer survival outcomes plus more toxicity versus rucaparib alone

Sep 18, 2024
ESMO over a photo of Fira Barcelona Gran Via in Barcelona, Spain.
Nasal Sprays for Respiratory Infections; Paxlovid in COVID Prevention

Also in TTHealthWatch: diabetes in kids after COVID

Jul 20, 2024
TTUHSC EL PASO HEALTHWATCH with their logo and photos of Rick Lange, MD, and Elizabeth Tracey
Risk of Ovarian Cancer Higher in Women With Endometriosis

Risk was highest in women with deep infiltrating endometriosis and/or ovarian endometriomas

Jul 18, 2024
 A computer rendering of ovarian cancer.
Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers

Clear cell histology "is what yields the super response we see in these trials," expert suggests

Jun 04, 2024
ASCO over a photo of McCormick Place in Chicago, IL
Lymphadenectomy Not Needed in Advanced Ovarian Cancer With Optimal Surgery

PFS was not significantly different for those who skipped lymphadenectomy

Jun 03, 2024
ASCO over a photo of McCormick Place in Chicago, IL
Estrogen-Only Therapy for Menopausal Symptoms Increases Ovarian Cancer Risk

Incidence, mortality double over 20 years, while estrogen plus MPA lowers endometrial cancer risk

May 24, 2024
ASCO over a photo of McCormick Place, in Chicago, IL
Novel PARP1 Inhibitor Shows Promise in Breast Cancer

The drug had favorable safety compared with first-generation PARP inhibitors in phase I/II study

Apr 09, 2024
AACR over a photo of San Diego Convention Center in San Diego, CA
Can Late-Stage Cancer Incidence Serve as an Endpoint for Screening Trials?

Study shows it may be an alternative to cancer-specific mortality for some cancers, but not all

Apr 08, 2024
AACR over a photo of San Diego Convention Center in San Diego, CA
Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers

About half of patients responded, duration of response as long as 19 months in three trials

Apr 05, 2024
FDA APPROVED trastuzumab deruxtecan (Enhertu) over a computer rendering of antibodies attacking cancer cells
Kate Middleton's Cancer: What to Know About 'Preventative' Chemotherapy

And what abdominal surgery could mean in the context of cancer

Mar 26, 2024
A photo of Kate Middleton, The Princess of Wales
Broader Cancer Risk With CAR-T? AI for Physician Burnout; 'Lollipops' ID Oral Cancer

News, features, and commentary about cancer-related issues

Mar 22, 2024
Onco Break over a computer rendering of a cancer cell.
Gynecologic Oncology May Face a Future of Too Few Cases, Too Many Docs

Subspecialists could see only one patient a week with a new cancer diagnosis, researcher says

Mar 18, 2024
SGO over a photo of San Diego Convention Center in San Diego, CA
Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer

Novel ADC targeting CDH6 achieves response in nearly 50% of patients

Mar 17, 2024
SGO over a photo of San Diego Convention Center in San Diego, CA
More in Ovarian Cancer